Induction of ferroptosis in prostate cancer by CCDC719-13 via TRIM21-mediated ubiquitination of SLC7A11
10.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-09-22 23:38
摘要：
CCDC719-13, a chimeric RNA, is identified as a prognostic marker in prostate cancer, significantly downregulated in high-grade and recurrent cases. It encodes a protein, CCDC7241aa, which induces ferroptosis through TRIM21-mediated ubiquitination of SLC7A11, leading to reduced tumor growth. The study demonstrates that CCDC7241aa can enhance the efficacy of existing therapies like docetaxel and enzalutamide, suggesting its potential as a therapeutic target in advanced prostate cancer.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
CCDC719-13 expression is significantly reduced in high-grade, recurrent, and metastatic prostate cancer tissues.
CCDC719-13 promotes ferroptosis by interacting with SLC7A11 and facilitating its TRIM21-mediated ubiquitination.
Recombinant CCDC7241aa effectively inhibits tumor growth in patient-derived xenograft models.
真实性检查
否
AI评分总结
CCDC719-13, a chimeric RNA, is identified as a prognostic marker in prostate cancer, significantly downregulated in high-grade and recurrent cases. It encodes a protein, CCDC7241aa, which induces ferroptosis through TRIM21-mediated ubiquitination of SLC7A11, leading to reduced tumor growth. The study demonstrates that CCDC7241aa can enhance the efficacy of existing therapies like docetaxel and enzalutamide, suggesting its potential as a therapeutic target in advanced prostate cancer.